Related Experiment Video

Updated: Nov 20, 2025

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.1K

Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases

Zhouling Xie1, Xiaoxiao Yang1, Yajun Duan1

  • 1Department of Pharmaceutical Sciences and Engineering, School of Food and Biological Engineering, Hefei University of Technology, Hefei 230009, China.

Journal of Medicinal Chemistry
|January 22, 2021
PubMed

Insights

Small-molecule kinase inhibitors, initially developed for cancer, show promise for treating diverse non-oncologic diseases like autoimmune and inflammatory conditions. Research highlights opportunities and challenges in expanding their therapeutic applications beyond oncology.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Drug Discovery

Background:

  • Kinase deregulation is implicated in numerous diseases beyond cancer, including autoimmune, inflammatory, cardiovascular, and central nervous system disorders.
  • Small-molecule kinase inhibitors have demonstrated significant success as anticancer therapeutics.
  • Emerging evidence identifies kinases as crucial drug targets for a wide spectrum of non-oncologic diseases.

Purpose of the Study:

  • To review kinases and their small-molecule inhibitors for treating non-oncologic diseases.
  • To discuss the therapeutic potential and development landscape of kinase inhibitors in non-oncologic fields.
  • To highlight the opportunities and challenges associated with developing kinase inhibitors for new disease indications.

Main Methods:

  • Literature review and synthesis of existing research on kinase inhibitors.
  • Analysis of approved kinase inhibitors and those in clinical trials for non-oncologic applications.
  • Discussion of specific kinases and their roles in various non-oncologic diseases.

Main Results:

  • The first non-oncologic small-molecule kinase inhibitor was approved by the U.S. FDA in 2011.
  • Ten small-molecule kinase inhibitors are currently approved for non-oncologic diseases.
  • Numerous kinase inhibitors are undergoing clinical trials for therapeutic applications outside of cancer treatment.

Conclusions:

  • Kinases represent a versatile class of drug targets with potential applications across numerous therapeutic areas.
  • The development of small-molecule kinase inhibitors offers significant opportunities for treating a broad range of non-oncologic diseases.
  • Addressing the challenges in developing these inhibitors is crucial for realizing their full therapeutic potential in diverse medical fields.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.3K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.3K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
317
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.5K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.6K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.0K